Fulcrum Therapeutics Stock
Fulcrum Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Alexander C. Sapir
- Employees
- 9
- Market cap
- $278 M
- IPO
- 18/07/2019
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting…
Fulcrum Therapeutics stock: price history
1D
-0.5%
1W
-3.2%
1M
-3.7%
6M
-56.0%
YTD
-67.7%
1Y
-60.7%
2Y
+0.8%
5Y
-86.0%
10Y
–
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~36% stronger price swings than usual
Ask the agents about Fulcrum Therapeutics
Analyst assessment of Fulcrum Therapeutics
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.60
MEDIAN
US$4.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
7
BUY
7
HOLD
3
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 03/06/2026
Fulcrum Therapeutics stock metrics
P/E
-3.02
P/B
0.9
EV/EBITDA
-3.04
RETURN ON EQUITY
-8.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.2%
FLOAT SHARES
63,490,762
AVG. DAILY VOLUME (30D)
1,425,245
Insider transactions (SEC)
TANG KEVIN
TANG KEVIN
TANG KEVIN
TANG KEVIN
TANG KEVIN
Institutional holders
Comparable stocks
Frequently asked questions about Fulcrum Therapeutics stock
What does Fulcrum Therapeutics do?
Fulcrum Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Alexander C. Sapir, the company employs around 9 people.
The IPO was on 18/07/2019; the stock trades on NASDAQ under the ticker FULC.
What do analysts say about Fulcrum Therapeutics stock?
17 analysts rate the stock, the consensus is Buy (as of 03/06/2026).
The average price target is US$3.60, ranging from US$3.00 to US$4.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Fulcrum Therapeutics report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 36% stronger than usual.
Does Fulcrum Therapeutics pay a dividend?
No, Fulcrum Therapeutics currently does not pay a dividend.
Which stocks are comparable to Fulcrum Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Fulcrum Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Fulcrum Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.